Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

nemolizumab

- PMLiVE

Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

Some patients found the treatment reduced itch and sleep disturbance within just two days

- PMLiVE

Galderma shares positive long-term data for Nemluvio in prurigo nodularis

The chronic skin disorder is estimated to affect up to 181,000 people in the US

- PMLiVE

Galderma shares positive two-year results for Nemluvio in atopic dermatitis

The chronic inflammatory skin disease affects more than 230 million people worldwide

- PMLiVE

MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

- PMLiVE

EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha

- PMLiVE

CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis

The drug has been recommended for use in patients with moderate-to-severe cases of the skin diseases

- PMLiVE

Galderma announces positive late-stage results for nemolizumab in prurigo nodularis

The chronic skin condition is estimated to affect up to 181,000 people in the US

- PMLiVE

FDA approves Galderma’s IL-31 inhibitor Nemluvio to treat prurigo nodularis in adults

The chronic skin condition is estimated to affect up to 181,000 people in the US

- PMLiVE

Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial

The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US

- PMLiVE

Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

- PMLiVE

Sanofi and Regeneron’s Dupixent granted EC approval for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links